VXUS - Vanguard Total International Stock ETF

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
52.65
-0.87 (-1.63%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close53.52
Open52.75
Bid0.00 x 38800
Ask0.00 x 800
Day's Range52.25 - 52.75
52 Week Range52.25 - 61.17
Volume1,118,915
Avg. Volume671,098
Net Assets356.43B
NAV55.32
PE Ratio (TTM)N/A
Yield2.84%
YTD Return-1.03%
Beta (3y)0.93
Expense Ratio (net)0.11%
Inception Date2011-01-26
Trade prices are not sourced from all markets
  • InvestorPlace2 months ago

    Build a Total Portfolio With Just 5 Vanguard ETFs

    There’s a reason why money continues to flow into exchange-traded funds (ETFs) and other indexed products. Passive and indexed portfolios take the guesswork out of market-timing decisions because index funds own all the stocks within a certain market segment. Buying index funds on a regular schedule and sticking to that plan is one of the best things you do for your portfolio.

  • Weekly Research Briefing: Risk in Traveling
    Harvest Exchange2 months ago

    Weekly Research Briefing: Risk in Traveling

    June 11, 2018 The international financial markets remain full of fear and doubt causing those who look abroad to remain cautious. This hesitancy to commit new monies overseas continues to benefit U.S. risk assets. While most global risk assets pulled ...

  • Morningstar4 months ago

    3 ETF Retirement Saver Portfolios for Taxable Accounts

    Composed of broad-market equity ETFs and smaller allocations to municipal bonds, these portfolios are designed for retirement savers' taxable accounts.

  • 3 Low-Cost International Funds to Last a Lifetime
    InvestorPlace4 months ago

    3 Low-Cost International Funds to Last a Lifetime

    Trying to find low-cost international funds can make that heartburn worse. While domestic companies, reporting requirements and regulatory standards do a pretty good job of preventing fraud, we have certainly seen our share of stocks implode as a result of such fraud. It can be very difficult to analyze the fundamentals of a foreign company, so I generally suggest that people stick to mutual funds and exchange-traded funds when it comes to investing internationally.

  • Why Investors Should Monitor Geopolitical Risks
    Market Realist6 months ago

    Why Investors Should Monitor Geopolitical Risks

    Localized geopolitical risks like the tension in the Middle East are unlikely to cause substantial damage to the markets in the long run, though they could bolster oil prices in the short term. The tension in the Korean Peninsula could be the biggest danger to market stability in the long run. As long as the balance is maintained between US interests and North Korea’s ambitions, the status quo is likely to prevail.

  • A Deeper Look at Valeant Pharmaceuticals’ Recent Financial Performance
    Market Realist6 months ago

    A Deeper Look at Valeant Pharmaceuticals’ Recent Financial Performance

    Why Some Investors Are Eying Valeant in 2018

  • What’s behind the Stock Market Fall?
    Market Realist6 months ago

    What’s behind the Stock Market Fall?

    What Triggered the Stock Market Panic This Month? The last two trading sessions on February 2 and 5 have left many investors worried about assets in the bond (BND) and stock markets. The sell-off in the stock market began after the US employment report was published on Friday, February 2.

  • Analysts’ Recommendations for Novartis after Its 4Q17 Earnings
    Market Realist6 months ago

    Analysts’ Recommendations for Novartis after Its 4Q17 Earnings

    Must-Read Notes on Novartis’s 4Q17 and 2017 Earnings

  • GlaxoSmithKline Projects Tough Environment for Triumeq and Tivicay
    Market Realist6 months ago

    GlaxoSmithKline Projects Tough Environment for Triumeq and Tivicay

    In 3Q17, dolutegravir franchise drugs Triumeq and Tivicay were major drivers of GlaxoSmithKline’s (GSK) rising HIV portfolio revenues. Triumeq and Tivicay are marketed by ViiV Healthcare, a joint venture of GlaxoSmithKline, Pfizer (PFE), and Shinogi. At the end of 3Q17, GlaxoSmithKline had estimated the overall market share of dolutegravir-based regimens to be around 26% in the US, higher than the 23% market share measured at the beginning of 2017.

  • What Analysts Recommend for GlaxoSmithKline in January 2018
    Market Realist7 months ago

    What Analysts Recommend for GlaxoSmithKline in January 2018

    In 3Q17, GlaxoSmithKline (GSK) reported global sales close to 7.8 billion pounds, which is a year-over-year (or YoY) rise of 2% on a constant exchange rate (or CER) basis and 4% YoY growth on an actual exchange rate (or AER) basis. The company reported earnings per share (or EPS) close to 24.8 pounds in 3Q17, which is a YoY rise of 46% on a CER basis and 49% on an AER basis. GlaxoSmithKline also reported adjusted EPS close to 32.5 pounds in 3Q17 and expects to witness a 3% to 5% YoY rise in adjusted EPS for 2017.

  • How Is Novartis’s Kymriah Positioned for 2018?
    Market Realist7 months ago

    How Is Novartis’s Kymriah Positioned for 2018?

    In January 2018, the U.S. FDA (Food and Drug Administration) accepted Novartis’s (NVS) supplemental biologics license application (or SBLA) for Kymriah suspension for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (or DLBCL) who are not candidates for autologous stem cell transplant (or ASCT). The U.S. FDA granted Novartis’s sBLA for priority review. Also, the European Medicines Agency (or EMA) granted accelerated assessment to the marketing authorization application (or MAA) for Novartis’s Kymriah for the treatment of children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (or ALL) and also for adults with relapsed or refractory DLBCL who are not candidates for ASCT.

  • Teva Pharmaceutical: Still Focused on New Product Launches
    Market Realist7 months ago

    Teva Pharmaceutical: Still Focused on New Product Launches

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? The Vanguard Total International Stock ETF (VXUS) holds 0.09% of its total portfolio in TEVA stock. Teva Pharmaceutical Industries (TEVA) has its biggest value chain in the market as the company’s core strength, which has helped it establish itself as the leading generics pharmaceutical company in the world.

  • How Teva Pharmaceutical Plans to Improve Financial Profile
    Market Realist7 months ago

    How Teva Pharmaceutical Plans to Improve Financial Profile

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As we saw in the previous part of this series, Teva Pharmaceutical Industries (TEVA) is determined to pay down a considerable amount of its debt totaling $32 billion over the next few years. The company aims to achieve financial stability through improvement in operating profits and stable cash flow generation over the next few years.

  • Best ETFs for 2018: Vanguard VSS ETF Is a Perfect One-Stop Shop for 2018
    InvestorPlace7 months ago

    Best ETFs for 2018: Vanguard VSS ETF Is a Perfect One-Stop Shop for 2018

    This article is a part of InvestorPlace’s Best ETFs for 2018 contest. TJeff Reeves’ pick for the contest is the Vanguard FTSE All World Ex-U.S. Small Cap ETF (NYSEARCA:VSS). After all, the big headlines last year always seemed to be talking about President Donald Trump, or the broad-based rally in stocks or sometimes the two at the same time.

  • ETF Trends8 months ago

    An Economical International ETF Luring U.S. Investors

    Investors are widely embracing low-fee international exchange traded funds in 2017. With international equities outpacing U.S. stocks and luring U.S. investors in the process, investors would do well to ...

  • International ETF (VXUS) Hits New 52-Week High
    Zacks8 months ago

    International ETF (VXUS) Hits New 52-Week High

    This international ETF hits a new 52-week high. Are more gains in store for this ETF?

  • GuruFocus.com8 months ago

    Jim Chanos: The Financial Detective

    Lessons for value investors in Chanos’ thoughts and actions

  • Morningstar9 months ago

    ETF Ratings Upgrades and Downgrades

    There have been few changes since we first began issuing Morningstar Analyst Ratings for ETFs one year ago, but we've ramped up coverage dramatically.

  • Kiplinger9 months ago

    3 Best International Mutual Funds to Play the Global Economic Recovery

    Why you should look overseas to grow your portfolio.

  • ETF.com10 months ago

    Perils Of Mixing ETF Fund Families

    Similar indexes can provide different exposures due to methodology.

  • ETF Trends11 months ago

    A Slim Fee ETF Bulging With International Stocks

    With international equities outpacing U.S. stocks and luring U.S. investors in the process, investors would do well to remember one of the largest ex-US exchange traded funds: The Vanguard Total International ...

  • Market Realist11 months ago

    How Are Novartis’s Blockbuster Drugs Gleevec and Tasigna Positioned?

    In 1H17, Novartis's (NVS) Gleevec reported revenues of around $1.1 billion, which reflected a ~39% decline on a year-over-year (or YoY) basis.